Diagnostics
Figure 3.
expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 104, 12–20 (1993).
4. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global Cancer Statistics, 2002. CA Cancer J Clin 55, 74–108 (2005).
5. Massarrat, S. & Stolte, M. Development of gastric cancer and its prevention. Arch Iran Med 17, 514–20 (2014).
low survival rates. However, there is a significant potential to identify this disease much earlier by looking at specific biomarkers – such as pepsinogen I, pepsinogen II, gastrin-17 and anti-H. pylori antibodies – using GastroPanel. Abnormal levels of these biomarkers, particularly a low pepsinogen I/II ratio, can indicate the presence of severe atrophic gastritis, which is a precursor to gastric cancer. Early identification through GastroPanel enables healthcare providers to initiate appropriate monitoring strategies, such as targeted surveillance with endoscopy and biopsies, and to implement lifestyle modifications or therapeutic interventions to manage the condition effectively. This proactive approach supports better patient outcomes by addressing risks early and guiding personalised management plans.
CSJ
References 1. Stomach cancer statistics. Cancer Research UK. 2. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011).
3. Wright, N. A. et al. Trefoil peptide gene
6. Lin, S.-H., Li, Y.-H., Leung, K., Huang, C.-Y. & Wang, X.-R. Salt Processed Food and Gastric Cancer in a Chinese Population. Asian Pacific Journal of Cancer Prevention 15, 5293–5298 (2014).
7. Buckland, G. et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer 137, 598–606 (2015).
8. Boltin, D. & Niv, Y. Pharmacological and alimentary alteration of the gastric barrier. Best Pract Res Clin Gastroenterol 28, 981–994 (2014).
9. Huang, R. J. & Hwang, J. H. Improving the Early Diagnosis of Gastric Cancer. Gastrointest Endosc Clin N Am 31, 503–517 (2021).
10. Sitarz, R. et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 10, 239–248 (2018).
11. Banks, M. et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma Gut 68,1545–1575 (2019).
12. Rugge, M. et al. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. American Journal of Gastroenterology 113, 1621–1628 (2018).
13. Rugge, M. et al. OLGA staging for gastritis: A tutorial. Digestive and Liver Disease 40, 650–658 (2008).
14. Fisher, L., Fisher, A. & Smith, P. N. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). J Clin Med 9, 3253 (2020).
About the author
Dr. Cinzia Papadia, MD, FRCP, is a Consultant Gastroenterologist & Honorary Senior Lecturer, at Barts Health Trust, Queen Mary University of London. She is an accredited Bowel Cancer Screening Endoscopist for North East London; a Fellow of the Royal College of Physician and Royal Society of Medicine, London; and a Member of the BSG Clinical Research Group, Food and Function. Her specific research interest is in novel clinical biomarkers of GI disease, with 940 research citations.
November 2024 I
www.clinicalservicesjournal.com 59
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
